• Addressing Global Inequalities in Comprehensive Cancer Care

    |

    Objective:
    The aim of this webinar is to highlight the collaborative efforts of SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, and AstraZeneca in expanding global access to and adoption of MSK-ACCESS® powered with SOPHiA DDM™, thereby addressing disparities in cancer care.

    Key Topics: 

    Transforming Cancer Care with MSK-ACCESS® powered with SOPHiA DDM™
    Explore the unique capabilities of MSK-ACCESS® powered with SOPHiA DDM™ in advancing precision medicine. Highlight the decentralized approach, the technology, and the analytical performance of this liquid biopsy application, aiming to ultimately transform cancer diagnosis and treatment globally.

    Closing the Gap: Reducing Inequalities in Global Cancer Care
    Discuss how the partnership between SOPHiA GENETICS, MSK, and AZ is addressing health inequalities by expanding access to state-of-the-art of MSK-ACCESS® powered with SOPHiA DDM™. Explore the key challenges and benefits associated with Liquid Biopsy adoption.  

    Strategic Alliances for Healthcare Innovation: Lessons from SOPHiA GENETICS, MSK, and AstraZeneca
    Explore the power and impact of strategic collaborations in driving healthcare innovation. Describe the shared objectives, complementary expertise, and collaborative efforts of SOPHiA GENETICS, MSK, and AstraZeneca in advancing precision oncology and setting new standards for interdisciplinary partnerships in the healthcare industry.




    Driving Innovation Together: SOPHiA GENETICS, MSK, and AstraZeneca’s Collaborative Partnership

    AstraZeneca’s Global Health Equity Approach: Expanding Access to Liquid Biopsy

    The Evolution of MSK-ACCESS®: From Inception to Validation and Global Adoption

    Q&A